Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
Abstract The clinical responses observed following treatment with immune checkpoint inhibitors (ICIs) support immunotherapy as a potential anticancer treatment. However, a large proportion of patients cannot benefit from it due to resistance or relapse, which is most likely attributable to the multi...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-09-01
|
| Series: | Molecular Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12943-022-01657-y |
| _version_ | 1818026165211758592 |
|---|---|
| author | Yuze Wu Ming Yi Mengke Niu Qi Mei Kongming Wu |
| author_facet | Yuze Wu Ming Yi Mengke Niu Qi Mei Kongming Wu |
| author_sort | Yuze Wu |
| collection | DOAJ |
| description | Abstract The clinical responses observed following treatment with immune checkpoint inhibitors (ICIs) support immunotherapy as a potential anticancer treatment. However, a large proportion of patients cannot benefit from it due to resistance or relapse, which is most likely attributable to the multiple immunosuppressive cells in the tumor microenvironment (TME). Myeloid-derived suppressor cells (MDSCs), a heterogeneous array of pathologically activated immature cells, are a chief component of immunosuppressive networks. These cells potently suppress T-cell activity and thus contribute to the immune escape of malignant tumors. New findings indicate that targeting MDSCs might be an alternative and promising target for immunotherapy, reshaping the immunosuppressive microenvironment and enhancing the efficacy of cancer immunotherapy. In this review, we focus primarily on the classification and inhibitory function of MDSCs and the crosstalk between MDSCs and other myeloid cells. We also briefly summarize the latest approaches to therapies targeting MDSCs. |
| first_indexed | 2024-12-10T04:27:40Z |
| format | Article |
| id | doaj.art-d7af662eb0644094891aa0f0c567beeb |
| institution | Directory Open Access Journal |
| issn | 1476-4598 |
| language | English |
| last_indexed | 2024-12-10T04:27:40Z |
| publishDate | 2022-09-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Cancer |
| spelling | doaj.art-d7af662eb0644094891aa0f0c567beeb2022-12-22T02:02:15ZengBMCMolecular Cancer1476-45982022-09-0121111910.1186/s12943-022-01657-yMyeloid-derived suppressor cells: an emerging target for anticancer immunotherapyYuze Wu0Ming Yi1Mengke Niu2Qi Mei3Kongming Wu4Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Breast Surgery, Zhejiang University School of Medicine First Affiliated HospitalDepartment of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and TechnologyAbstract The clinical responses observed following treatment with immune checkpoint inhibitors (ICIs) support immunotherapy as a potential anticancer treatment. However, a large proportion of patients cannot benefit from it due to resistance or relapse, which is most likely attributable to the multiple immunosuppressive cells in the tumor microenvironment (TME). Myeloid-derived suppressor cells (MDSCs), a heterogeneous array of pathologically activated immature cells, are a chief component of immunosuppressive networks. These cells potently suppress T-cell activity and thus contribute to the immune escape of malignant tumors. New findings indicate that targeting MDSCs might be an alternative and promising target for immunotherapy, reshaping the immunosuppressive microenvironment and enhancing the efficacy of cancer immunotherapy. In this review, we focus primarily on the classification and inhibitory function of MDSCs and the crosstalk between MDSCs and other myeloid cells. We also briefly summarize the latest approaches to therapies targeting MDSCs.https://doi.org/10.1186/s12943-022-01657-yMyeloid-derived suppressor cellsCancer immunotherapyImmune checkpoint inhibitorsThe tumor microenvironmentArginase IInducible nitric oxide synthase |
| spellingShingle | Yuze Wu Ming Yi Mengke Niu Qi Mei Kongming Wu Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy Molecular Cancer Myeloid-derived suppressor cells Cancer immunotherapy Immune checkpoint inhibitors The tumor microenvironment Arginase I Inducible nitric oxide synthase |
| title | Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy |
| title_full | Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy |
| title_fullStr | Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy |
| title_full_unstemmed | Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy |
| title_short | Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy |
| title_sort | myeloid derived suppressor cells an emerging target for anticancer immunotherapy |
| topic | Myeloid-derived suppressor cells Cancer immunotherapy Immune checkpoint inhibitors The tumor microenvironment Arginase I Inducible nitric oxide synthase |
| url | https://doi.org/10.1186/s12943-022-01657-y |
| work_keys_str_mv | AT yuzewu myeloidderivedsuppressorcellsanemergingtargetforanticancerimmunotherapy AT mingyi myeloidderivedsuppressorcellsanemergingtargetforanticancerimmunotherapy AT mengkeniu myeloidderivedsuppressorcellsanemergingtargetforanticancerimmunotherapy AT qimei myeloidderivedsuppressorcellsanemergingtargetforanticancerimmunotherapy AT kongmingwu myeloidderivedsuppressorcellsanemergingtargetforanticancerimmunotherapy |